statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced that it...

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, announced today...

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced...

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences, Inc. (Nasdaq: PLSE) (Pulse or the Company), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced that the...

Pulse Biosciences CellFX Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced CellFX nsPFA technology will be...

Pulse Biosciences Enhances Executive Leadership Team

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology (Pulse), today announced enhancements to its...

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced the first procedure with the CellFX...

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced business updates and financial...

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Volume	237,638.00
52-Wk High	$20.44
52-Wk Low	$3.78

PLSE Pulse Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals